杨森制药的厄达替尼在国内买的到吗？

(Erdafitinib) is a new drug for the treatment of urothelial cancer in adults. Astex Pharmaceuticals of the United States and Janssen Pharmaceuticals, a subsidiary of the Johnson & Johnson Pharmaceutical Group, jointly discovered the pan-FGFR gene mutation inhibitor erdafitinib, a new drug that can treat urothelial cancer, in June 2008, and signed an agreement with Janssen Pharmaceuticals to authorize Janssen Biotechnology to conduct global licensing, development and commercialization of promising inhibitors discovered in FGFR research projects.

In April 2011, Astex Therapeutics was acquired by SuperGen, Inc. of the United States. The name of the merged entity is still Astex Pharmaceuticals. The company was acquired by Japan's Otsuka Pharmaceuticals in October 2013 and became a wholly-owned subsidiary of Otsuka Pharmaceuticals. In March 2018, the U.S. Food and Drug Administration (FDA) granted erdafitinib breakthrough therapy designation for the treatment of urothelial cancer.

Janssen Pharmaceuticals was established on October 22, 1985. It is a modern pharmaceutical enterprise jointly established by Shaanxi Pharmaceutical Corporation, Shaanxi Hanjiang Pharmaceutical Co., Ltd., China National Pharmaceutical Industry Corporation and China National Pharmaceutical Foreign Trade Corporation and Janssen Pharmaceuticals of Belgium. It submitted a new drug application to the U.S. FDA on September 18, 2018. The FDA accelerated the marketing approval of erdafitinib on April 12, 2019, for the treatment of adults with locally advanced or metastatic urothelial carcinoma susceptible to FGFR3 or FGFR2 gene mutations, who have received at least first-line platinum-containing chemotherapy drugs, including neoadjuvant or adjuvant platinum-containing chemotherapy drugs within 12 months, and the disease has progressed during or after treatment.

Although the drug has been successfully approved for marketing overseas, Janssen Pharmaceuticals has not yet officially launched it in China, so patients still cannot buy the drug in China. However, patients in need can contact Medical Travel to purchase medicine overseas.

Recommended hot articles: /newsDetail/96484.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.